Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

18.50 -0.60 (-3.14%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >

Amneal Pharmaceuticals Q2 Earnings Call Highlights ↗

Today 10:04 EDT

Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at...

Via MarketBeat

Topics Earnings

Amneal Pharmaceuticals (NASDAQ:AMRX) Soars on Q2 Earnings Beat and Raised Guidance ↗

Today 7:40 EDT

Via Chartmill

Topics Earnings

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%

Today 6:21 EDT

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on ...

Via StockStory

Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings

July 28, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here’s what to expect. Amn...

Via StockStory

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗

February 27, 2026

Via Chartmill

Topics Earnings

Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1

July 27, 2026

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Reasons AMRX is Risky and 1 Stock to Buy Instead

July 15, 2026

Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The...

Via StockStory

Topics Stocks

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

July 06, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Mooning Stock Worth Your Attention and 2 We Question

June 29, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Via StockStory

1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky

June 17, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

3 Russell 2000 Stocks with Open Questions

June 10, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗

June 09, 2026

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics...

Via MarketBeat

Why Amneal (AMRX) Stock Is Trading Up Today

June 04, 2026

What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Admini...

Via StockStory

3 Profitable Stocks with Open Questions

June 04, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Topics Economy

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

May 26, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Reasons AMRX is Risky and 1 Stock to Buy Instead

May 12, 2026

Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. ...

Via StockStory

Topics Artificial Intelligence Stocks

Amneal (AMRX) Q3 2025 Earnings Call Transcript ↗

May 04, 2026

Amneal (AMRX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Amneal (AMRX) Q2 2025 Earnings Transcript ↗

May 04, 2026

Amneal (AMRX) Q2 2025 Earnings Transcript

Via The Motley Fool

Topics Supply Chain

1 Value Stock to Target This Week and 2 Facing Challenges

May 04, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Amneal (AMRX) Q1 2026 Earnings Transcript ↗

May 01, 2026

Amneal (AMRX) Q1 2026 Earnings Transcript

Via The Motley Fool

Amneal (AMRX) Q1 Earnings Report Preview: What To Look For

April 29, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know. Amneal ...

Via StockStory

Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ...

Via StockStory

Topics Economy

2 Cash-Producing Stocks to Research Further and 1 We Brush Off

April 13, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Via StockStory

3 of Wall Street’s Favorite Stocks We Steer Clear Of

April 08, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

3 Small-Cap Stocks Walking a Fine Line

March 30, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment

March 10, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Reasons to Avoid AMRX and 1 Stock to Buy Instead

March 10, 2026

Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may hav...

Via StockStory

Topics Stocks

3 Value Stocks We’re Skeptical Of

March 05, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

Why Amneal (AMRX) Stock Is Trading Lower Today

February 27, 2026

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell 6.3% in the afternoon session after the company reported fourth-quarter results that beat expectations but provided a...

Via StockStory

Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Amneal (AMRX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.